The prevalence of MASLD (metabolic dysfunction-associated steatotic liver disease) is exploding in most regions of the world, boosted by increased obesity and sedentary lifestyles. MASLD (formerly known as non-alcoholic fatty liver disease) is already the most common liver disorder: it affects 30% of adults and between 7% and 14% of children and adolescents, and this prevalence is predicted to rise to more than 55% of adults by 2040.
FDA approves RSV monoclonal antibody for infants, young children at high risk
The Food and Drug Administration approved a monoclonal antibody to protect infants and young children from severe illness caused by RSV on Monday, a potential
July 17, 2023